AUSTIN -- State leaders announced the construction Tuesday of a $91 million vaccine-manufacturing center at Texas A&M University that they say will create thousands of jobs while protecting the country against future biological threats and influenza pandemics.Gov. Rick Perry, A&M System Chancellor John Sharp and others gathered at the Capitol to discuss the collaboration among A&M, pharmaceutical giant GlaxoSmithKline and the federal government.Details of the center were released in July, but the Health and Human Services Department recently gave federal approval to establish the center, which will be built in College Station."Not only will this center keep Americans safer from epidemic, it will bring in more than $41 billion to the state over the next 25 years and contribute to the creation of more than 6,800 jobs in Texas," Perry said.The center will eventually give GlaxoSmithKline the ability to make influenza vaccine -- up to 50 million doses within four months of an outbreak. The center will also dramatically boost the domestic capacity of the United States to quickly produce drugs needed after a chemical or biological attack, said Robin Robinson, director of the federal Biomedical Advanced Research and Development Authority."This is part of the solution to provide domestic security for this nation for biodefense or against Mother Nature," Robinson said. "This partnership will serve not only the nation, but the globe in terms of vaccines and other therapies."The Texas A&M Center for Innovation in Advanced Development and Manufacturing was established with an initial federal, local and private investment of $285.6 million, and the new facility will be built with some of that money.